Objective: To identify at species level, in a prospective study in a tertiary university hospital during the two years 1996 and 1997, all isolates of Campylobacferspp. and related organisms and to determine their susceptibility to erythromycin and ciprofloxacin.
INTRODUCTION
Campylobacter spp. represent the leading cause of acute bacterial diarrhea in developed countries [1, 2] . The predominant species is Campylobacter jejuni, followed by C. coli [1, 3] . Extraintestinal infections such as bacteremia occur more rarely, mainly in immuno-compromised patients, and are due to various species of Campylobacter and related organisms [3, 4] .
During the last decade, the taxonomy of Cumpylobacter spp. and related organisms has been extensively revised and, based on molecular data, it now includes the genera Campylobacter, Arcobacter and Helicobacter (5, 6] . Campylobacters are fastidious microorganisms, and complete identification to species level is rarely performed in microbiology laboratories, where they are frequently reported as ' Campylobacter jejuni/colr". Thus the incidence and clinical si@cance of newly described species of Campylobacter and related organisms remain largely unknown.
The treatment of choice for infections with C. jejuni and C. coli includes erythromycin or fluoroquinolones [3] . Fluoroquinolones are often given empirically to treat suspected gastroenteritis because they are active against all of the main enteric pathogens. In recent years, the emergence and spread of resistance in campylobacters, mainly to fluoroquinolones r/-121 but also to macrolides [9,11,13-151, has been reported in different countries.
The aim of the present prospective study was twofold. First, all campylobacters and related organisms isolated h m stools or blood during the two years 1996 and 1997 were identified to species level by phenotypic and genotypic methods, in order to assess their occurrence and clinical significance. Second, their susceptibility to erythromycin and ciprofloxacin was determined to estimate the prevalence of clinically significant resistance and to evaluate current therapeutic recommendations.
MATERIALS AND METHODS

Patients
The university hospital of Geneva is a 1300-bed healthcare center providing primary and tertiary care for Geneva and the surrounding area. The detection of Campylobacter spp. was performed systematically for all patients for whom a bacterial analysis of feces was requested. 
Specimens and culture
Dot-blot DNA hybridization
This was performed as described previously [20] . Briefly, genomic DNA was extracted &om clinical isolates by &ne lysis and spotted onto filters. The filters were then hybridued under stringent conditions with digoxigenin-labeled genomic DNA of the corresponding type strains, and the resulting hybrids were detected by the chromogenic alkaline phosphatase protocol proposed by the manufacturer (Boehringer Mannheim, Mannheim, Germany). 
Antimicrobial susceptibilii testing
RESULTS
During the two years 1996 and 1997,140 patients were found to be infected by Campylobacter spp. or related organisms, including 133 patients with gastroenteritis and seven patients with bacteremia. Detailed clinical findings of patients with bacteremia and those with gastroenteritis due to species other than C. jejuni and C. coli are summarized in Table 1 . Of the 140 patients, 60 (42.9%) were female. The mean age of patients with gastroenteritis was 29.8 years (range: 40 days to 94 years), and that for patients with bacteremia was 57.7 years (range: 25-86 years). Children below the age of 16 years represented one-third (47 patients) of the patients infected by campylobacters. The peak incidence was observed during the 4 months of June to September, representing 69 (49%) of the infected patients. Five of the seven cases with bacteremia occurred during the summer. Of the seven patients with gastroenteritis due to species other than C. jejuni or C. coli, five were irnmunocompromised and three (one Arcobactw butzleri, one C. fetus, one Helicobacter pullorurn) were acquired during the hospital stay. Three of the seven bacteremias (two C. fetus, one C. jejuni) were also acquired during the hospital stay. In total, 142 isolates, including 135 fecal isolates and seven blood isolates, were analyzed. For one patient, C. jejuni was isolated from both feces and blood. Another patient with gastroenteritis was concomitantly infected by C. jejuni and C. coli. The results of identification and the detailed results of biochemical tests are presented in Table 2 . All isolates in the present study were oxidase positive. In Gram-staining, the four isolates of A. butzleri appeared to be less curved than Cumpylobarter spp. Three hippurate-negative Cumpylobucter isolates were identified as C. jejuni by DNA hybridization; the identity was further confirmed by a positive hybridization signal on Southern blots with a probe for the hippuricase gene [23] (data not shown).
Antimicrobial susceptibility
The distribution of MICs for ciprofloxacin and erythromycin is presented in [6,26] .
The isolates of C. fetus, Helicobacter. spp. and A. butrlm' do not grow at 42OC [6,27], a temperature fiequently used in microbiology laboratories for isolation of campylobacters fipm stools. This may explain the underestimation of these species by routine microbiology laboratories. We never reported A. butzlm' or C. fetus fipm stools when we used a tempera-of 42OC instead of 35OC for isolation of campylobacters, prior to this study [28] . It is well recognized now that phenotypic methods do not allow accurate identification of all campylobacters, and that the genetic methods, such as nucleic acid probes, represent a powerful identification tool [27] . As genotypic methods are not routinely used in clinical microbiology laboratories, we recommend the strategy of identification applied in the present study, in which phenotypic methods represent the first-line measure and genotypic methods are used for definitive identification of all campylobacters. Primarily, we used phenotypic characterization with Gram-staining (ArcobaEter spp. are less curved than Campylobucter), basic phenotypic tests such as oxidase and catalase (Atwbacter spp. have a negative or weakly positive catalase test), susceptibility to polymyxin B (ffeluobacter spp. except for H. pullorurn 30] , and will allow a better understanding of the pathogenicity and epidemiology of campylobacters.
The determination of the antimicrobial susceptibility of campylobacters can be easily performed by Etest in routine laboratories [21,22,31] . The determination of MICs allows comparison of results f b m Merent studies, even if the applied breakpoints are Merent fipm one study to another in relation to the lack of specific recommendations for campylobacters by the NCCLS [32] . In the present study, 15% of C. jejwni were found to be resistant to fluoroquinolones, a rate higher than the 3% of quinolone resistance reported in Switzerland in 1990 by Adler-Mosca and Altwegg [7], but lower than those reported elsewhere. In Spain, up to 50% of campylobacters were resistant to fluoroquinolones [14], and in Thailand an explosive increase was noted, with 84% of campylobacters found to be resistant to fluoroquinolones and 15% to macrolides [9]. The development of antimicrobial resistance of campylobacters varies f b m one country to another and may be linked to the use of antimicrobial agents in human and veterinary medicine [33] . In Switzerland, a recent study [34] reported a low rate of quinolone resistance among veterinary isolates of campylobacters (4%); this may be related to the limited veterinary use of quinolones. In human medicine, although the majority of cases of gastroenteritis due to Carnpylobacter do not require specific antimicrobial treatment, antimicrobial therapy is necessary for severe enterocolitis and extraintestinal manifestations [3] . It is based on macrolides or fluoroquinolones and is often started on an empirical basis, because the result of antimicrobial susceptibility is generally obtained afier the beginning of therapy. In these circumstances, the choice of antimicrobial agent should be based on the susceptibility pattern of a given counq.
In conclusion, microbiology laboratories must detect and accurately identify campylobacters, the leading cause of gastroenteritis and potential invasive pathogens in immunocompromised patients. The routine identification of C. jejuni at the species level is accessible for clinical microbiology laboratories, but the other species require genotypic methods. The determination of antimicrobial susceptibility of campylobacters is easily performed by the Etest and is useful for both clinicians and surveillance of antimicrobial resistance.
